Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Author:
Funder
Arthritis Research UK
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference102 articles.
1. B-cell targeting in rheumatoid arthritis and other autoimmune diseases;Edwards;Nat. Rev. Immunol.,2006
2. A review of the current use of rituximab in autoimmune diseases;Gurcan;Int. Immunopharmacol.,2009
3. Anti-CD20 monoclonal antibodies: historical and future perspectives;Lim;Haematologica,2010
4. Interindividual variability of response to rituximab: from biological origins to individualized therapies;Cartron;Clin. Cancer Res.,2011
5. Mechanisms of killing by anti-CD20 monoclonal antibodies;Glennie;Mol. Immunol.,2007
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy;Kidney International Reports;2024-08
2. Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult;Frontiers in Immunology;2024-07-29
3. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?;Clinical and Experimental Immunology;2024-04-20
4. Rheumatoid arthritis: pathogenesis and therapeutic advances;MedComm;2024-03
5. Advancing rheumatic disease treatment: A journey towards better lives;Open Health;2024-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3